Do Not Take a Broken Brukinsa Tablet
If your Brukinsa (zanubrutinib) tablet is broken or has a piece missing, do not take it—contact your healthcare provider or pharmacist for a replacement. The FDA prescribing information explicitly states that patients should "swallow capsules whole with water" and "not open, break, or chew the capsules" 1.
Why This Matters
Dosing Precision is Critical
Brukinsa requires precise dosing for optimal efficacy and safety. The standard dose is either 160 mg twice daily or 320 mg once daily 1. Taking a broken tablet means you cannot accurately determine how much medication you're receiving, which can lead to:
- Underdosing: Potentially reducing treatment effectiveness against your B-cell malignancy
- Overdosing: If you attempt to compensate by taking additional pieces, increasing risk of adverse events including bleeding complications, infections, and cytopenias 2
Drug Stability Concerns
When tablets break, the active ingredient (zanubrutinib) becomes exposed to:
- Light and moisture, which may degrade the drug 3
- Altered absorption characteristics that could affect blood levels 3
The integrity of the tablet formulation is designed to deliver consistent drug exposure—breaking this compromises that design 4.
What to Do Instead
- Contact your pharmacy immediately for a replacement tablet
- Do not attempt to estimate dosing by taking partial tablets
- If you miss a dose while waiting for replacement: Take it as soon as possible on the same day, then return to your normal schedule the following day 1
- Store tablets properly at room temperature (68°F to 77°F) in the child-resistant bottle to prevent future breakage 1
Important Safety Context
Brukinsa carries significant risks that require precise dosing management, including serious bleeding (potentially fatal), severe infections, and cardiac arrhythmias 1, 2. The medication also requires dose modifications for drug interactions and hepatic impairment 1—making accurate dosing even more critical.
The tablet formulation was specifically developed to reduce pill burden (2 tablets vs 4 capsules) while maintaining bioequivalence and consistent drug exposure 4. Breaking tablets undermines this pharmaceutical design.